Last reviewed · How we verify
approved egg-derived TIV — Competitive Intelligence Brief
phase 3
Biologic
Live · refreshed every 30 min
Target snapshot
approved egg-derived TIV (approved egg-derived TIV) — UMN Pharma Inc..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| approved egg-derived TIV TARGET | approved egg-derived TIV | UMN Pharma Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- approved egg-derived TIV CI watch — RSS
- approved egg-derived TIV CI watch — Atom
- approved egg-derived TIV CI watch — JSON
- approved egg-derived TIV alone — RSS
Cite this brief
Drug Landscape (2026). approved egg-derived TIV — Competitive Intelligence Brief. https://druglandscape.com/ci/approved-egg-derived-tiv. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing